Back to search
FDAFDA · Food and drugs·Recall number D-0467-2024

Abilify (aripiprazole), 10 mg tablets, packaged in a) 30 count bottles (NDC 59148-008-13) and b) 7 count blister packs (NDC 59148-008-95), RX only, Otsuka America Pharmaceutical, Inc.

Published May 1, 2024 · Recall initiated: April 9, 2024

Summary

FDA records drug Class III recall D-0467-2024, published May 1, 2024 and initiated April 9, 2024. Recalling firm: Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.; Status: Ongoing; Reported quantity: N/A; Lot: Lot #: a) ALS00422A, Exp 04/30/2025; ALS00523A, Exp 11/30/2025; b) 1K77YUD1H1A, Exp 11/30/2024. Class III means the product is not likely to cause adverse health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cross Contamination with Other Products

What to do

Voluntary: Firm initiated · Letter

Get an email if ABILIFY has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
ABILIFY
Manufacturer
Second Tokushima Factory, Otsuka Pharmaceutical Co., Ltd.
Distributor
USA nationwide.
Lot
Lot #: a) ALS00422A, Exp 04/30/2025; ALS00523A, Exp 11/30/2025; b) 1K77YUD1H1A, Exp 11/30/2024
Risk classification
Class III
Area (FDA)
drug
Country
Japan

Related recalls

Questions about this recall

Was Abilify (aripiprazole), 10 mg tablets, packaged in a) 30 count bottles (NDC 59148-008-13) and b) 7 count blister packs (NDC 59148-008-95), RX only, Otsuka America Pharmaceutical, Inc. recalled?

Yes. FDA published recall D-0467-2024 on May 1, 2024. Reported hazard: Cross Contamination with Other Products

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: ABILIFY.